The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.
RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
Most people using finasteride, minoxidil, or dutasteride for hair loss experience maintenance or regrowth, but they often don't discuss it publicly. Online forums may not accurately represent the typical success rates, as satisfied users rarely share their positive outcomes.
The conversation is about using a product containing dutasteride and tamsulosin for hair loss. Users discuss separating the components and potential side effects like frequent urination and changes in libido.
The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.
The user is experiencing a significant hair shed at 10 months but sees improvement compared to 4 months ago. They are using Hims products, Feel Confident shampoo, Nizoral, a light therapy cap, and The Ordinary hair serum.
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.
The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.
The conversation is about recommending safe and effective dermaroller or dermastamp brands for hair loss treatment. Users discuss avoiding cheap options to prevent scalp damage and share usage frequency.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.
The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.
User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.
The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.
The user is experiencing scalp irritation and hair thinning, possibly due to stress, with red patches on the face and dry skin. They are considering seeing a dermatologist and have used tea tree and rosemary oil.
The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
The conversation discusses using a hair wax containing propolis and Eruca sativa seed oil for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.